HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.

AuthorsKrzysztof Giannopoulos, Anna Dmoszyńska, Jacek Roliński
JournalLeukemia research (Leuk Res) Vol. 31 Issue 3 Pg. 411-2 (Mar 2007) ISSN: 0145-2126 [Print] England
PMID16978694 (Publication Type: Comment, Letter)
Chemical References
  • Tumor Necrosis Factor-alpha
  • Thalidomide
  • Cyclophosphamide
  • Vidarabine
  • fludarabine
Topics
  • Administration, Oral
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Cyclophosphamide (administration & dosage)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Follow-Up Studies
  • Humans
  • Injections, Intravenous
  • Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, pathology)
  • Recurrence
  • Remission Induction
  • T-Lymphocytes, Regulatory (drug effects)
  • Thalidomide (administration & dosage)
  • Treatment Failure
  • Tumor Necrosis Factor-alpha (blood)
  • Vidarabine (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: